(VIANEWS) – The Market ended the session with MAAT PHARMA (MAAT.PA) jumping 10.75% to €8.86 on Wednesday while CAC 40 rose 0.68% to €6,932.63.
MAAT PHARMA’s last close was €8.00, 27.93% below its 52-week high of €11.10.
About MAAT PHARMA
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.4.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.11%.
More news about MAAT PHARMA (MAAT.PA).
